$LLY: Decision Zone — Wedge Breakout or Retest of 685Eli Lilly (LLY) rebounded off the long-term trendline and weekly demand box (≈622–686) and is compressing inside a descending wedge.
Bullish path (blue): a clean break and retest of wedge resistance opens room toward the prior extension/marker near ~970.
Bearish path (red): rejection at the
Key facts today
Analysts from HSBC, Morgan Stanley, and Truist are optimistic about Eli Lilly, with projections of Orforglipron's sales reaching up to $25 billion annually by 2032.
Eli Lilly plans to invest $27 billion to build four new manufacturing facilities in the U.S. over the next five years, with two site locations expected to be announced this quarter.
Eli Lilly's olomorasib, combined with Merck's Keytruda, received FDA breakthrough designation for treating advanced non-small cell lung cancer with KRAS G12C mutation after positive trial results.
0.25 USD
9.41 B USD
40.01 B USD
About Eli Lilly and Company
Sector
Industry
CEO
David A. Ricks
Website
Headquarters
Indianapolis
Founded
1876
ISIN
ARDEUT111192
FIGI
BBG000HFVYP1
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Related stocks
Lilly Has Fallen. Can it Get Up?Eli Lilly has been trending lower, and some traders may see further downside risk in the pharma giant.
The first pattern on today’s chart is the bearish gap on August 7. The decline came despite better-than-expected quarterly results, which may reflect weakening fundamentals.
Second is the May 23
Eli Lilly (LLY) Weekly Chart – Double Top Patterns & Major SuppoLLY has formed consecutive double top patterns within a broad descending channel.
Price recently tested a long-term major support zone and bounced strongly, signaling renewed buying interest. If this momentum holds, a move toward the major resistance near $973 is possible, aligning with the upper
LLY - Clean Levels UpdatedEli Lilly's hit those 708.49 and 711 levels I mentioned in my previous LLY post.
I've added some weekly levels, and a couple relevant spots from my boxed LLY chart.
If LLY loses steam up here we could easily see a retest of that box top area in the $680 - $678 range. Otherwise if we see a market
LLY $720 Call Setup: Don’t Miss Out on This Breakout Play!🚀 LLY Weekly Options Analysis (2025-08-17) 🚀
### 🔎 Comprehensive Multi-Model Insights
**Grok/xAI Report**
* 📊 RSI: Neutral (Daily & Weekly \~46)
* 📈 Flow: Call/Put = **3.87 (Bullish bias)**
* 🔊 Volume: Weak vs. previous weeks → ⚠️ no strong institutional support
* 🛑 Trade: **No entry** (weak conf
LLY AUG-2025Eli Lilly ( NYSE:LLY ) rebounded strongly from the 640 support zone after institutional absorption. Price is now targeting the gap at 740, aligning with prior distribution levels. Sustained momentum above 700 could drive continuation into 737–740. Failure to hold above 640 risks a deeper move into t
Red Pill or Blue Pill?Red Pill first - let’s stick to some harsh realities, but using technical analysis only.
Why the harsh crash?
We were rejected at the Value Area high at $972, followed by another rejection at the 0.786 Fibonacci level at $916, along with the top of the flag pattern of this giant bull flag. This wa
See all ideas
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
LLY6153506
Eli Lilly and Company 4.0% 15-OCT-2028Yield to maturity
—
Maturity date
Oct 15, 2028
LLY.GV
Eli Lilly and Company 5.5% 15-MAR-2027Yield to maturity
—
Maturity date
Mar 15, 2027
LLY6153403
Eli Lilly and Company 4.9% 15-OCT-2035Yield to maturity
—
Maturity date
Oct 15, 2035
LLY6153502
Eli Lilly and Company 5.55% 15-OCT-2055Yield to maturity
—
Maturity date
Oct 15, 2055
LLY5750405
Eli Lilly and Company 4.7% 09-FEB-2034Yield to maturity
—
Maturity date
Feb 9, 2034
LLY5871803
Eli Lilly and Company 5.05% 14-AUG-2054Yield to maturity
—
Maturity date
Aug 14, 2054
LLY4099975
Eli Lilly and Company 4.65% 15-JUN-2044Yield to maturity
—
Maturity date
Jun 15, 2044
LLY6003397
Eli Lilly and Company 5.6% 12-FEB-2065Yield to maturity
—
Maturity date
Feb 12, 2065
LLY6003092
Eli Lilly and Company 5.1% 12-FEB-2035Yield to maturity
—
Maturity date
Feb 12, 2035
LLY5750031
Eli Lilly and Company 5.0% 09-FEB-2054Yield to maturity
—
Maturity date
Feb 9, 2054
LLY5547404
Eli Lilly and Company 4.875% 27-FEB-2053Yield to maturity
—
Maturity date
Feb 27, 2053
See all LLYD bonds